Education
About Us
Working with TipRanks
Follow Us
Prestige Consumer Healthcare (PBH)
NYSE:PBH
PBH Stock Chart & Stats
Day’s Range― - ―
52-Week Range$60.15 - $90.04
Previous CloseN/A
Volume57.25K
Average Volume (3M)530.16K
Market Cap
$3.00B
Enterprise Value$4.88B
Total Cash (Recent Filing)$139.50M
Total Debt (Recent Filing)$1.04B
Price to Earnings (P/E)14.5
Beta0.31
Next Earnings
Nov 06, 2025EPS Estimate
0.97Last Dividend Ex-Date
Sep 27, 2018Dividend YieldN/A
Share Statistics
EPS (TTM)0.95
Shares Outstanding49,214,172
10 Day Avg. Volume388,926
30 Day Avg. Volume530,160
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.63
Enterprise Value/Revenue4.36
Enterprise Value/Gross Profit7.76
Enterprise Value/Ebitda13.58
Forecast
1Y Price Target
$83.33Price Target Upside34.75% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Bulls Say, Bears Say
Bulls Say
Acquisition BenefitsThe acquisition of Pillar5 Pharma, a key supplier for PBH's eye care products, is expected to address supply issues and is not anticipated to negatively impact the company's financials.
Expansion And DiversificationPBH has further diversified its eye care manufacturing with new third-party partnerships and the acquisition of one of its partner's facility in Canada for $100M, which is expected to help the business start to recover.
Strategic InitiativesManagement's overall strategy around brand-building and utilizing disciplined M&A to grow the business can continue to drive strong FCF and shareholder returns despite the near-term topline headwinds from the eye care business.
Bears Say
Earnings QualityEarnings quality was soft with sales and gross margin below expectations.
Financial GuidanceThe company lowered its financial guidance for the year due to ongoing eye care constraints, impacting expectations.
Sales PerformancePBH reported lower-than-expected sales and earnings due to supply constraints in the eye care business, leading to a weaker performance in North America.
Prestige Consumer Healthcare News
PBH FAQ
What was Prestige Consumer Healthcare’s price range in the past 12 months?
Prestige Consumer Healthcare lowest stock price was $60.15 and its highest was $90.04 in the past 12 months.
What is Prestige Consumer Healthcare’s market cap?
Prestige Consumer Healthcare’s market cap is $3.00B.
When is Prestige Consumer Healthcare’s upcoming earnings report date?
Prestige Consumer Healthcare’s upcoming earnings report date is Nov 06, 2025 which is in 22 days.
How were Prestige Consumer Healthcare’s earnings last quarter?
Prestige Consumer Healthcare released its earnings results on Aug 07, 2025. The company reported $0.95 earnings per share for the quarter, missing the consensus estimate of $1 by -$0.05.
Is Prestige Consumer Healthcare overvalued?
According to Wall Street analysts Prestige Consumer Healthcare’s price is currently Undervalued.
Does Prestige Consumer Healthcare pay dividends?
Prestige Consumer Healthcare pays a Notavailable dividend of $0.475 which represents an annual dividend yield of N/A. See more information on Prestige Consumer Healthcare dividends here
What is Prestige Consumer Healthcare’s EPS estimate?
Prestige Consumer Healthcare’s EPS estimate is 0.97.
How many shares outstanding does Prestige Consumer Healthcare have?
Prestige Consumer Healthcare has 49,214,172 shares outstanding.
What happened to Prestige Consumer Healthcare’s price movement after its last earnings report?
Prestige Consumer Healthcare reported an EPS of $0.95 in its last earnings report, missing expectations of $1. Following the earnings report the stock price went down -10.045%.
Which hedge fund is a major shareholder of Prestige Consumer Healthcare?
Currently, no hedge funds are holding shares in PBH
Prestige Consumer Healthcare Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$83.33 (34.75% Upside)
$83.33 (34.75% Upside)
Blogger Sentiment
Bullish
PBH Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 220.1K Shares
Last Quarter.
Last Quarter.
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-11.12%
12-Months-Change
Fundamentals
Return on Equity
12.05%
Trailing 12-Months
Asset Growth
3.75%
Trailing 12-Months
Company Description
Prestige Consumer Healthcare
Prestige Consumer Healthcare (PBH) is a leading global company specializing in over-the-counter (OTC) healthcare products. The company operates in various sectors including pain relief, cold and allergy, personal care, and foot care. PBH's core offerings include well-known brands such as TheraGun, Dramamine, and Chloraseptic, among others, which cater to a wide range of consumer health needs.
PBH Company Deck
PBH Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Negative
The earnings call presented a mixed sentiment. While the company achieved significant gross margin expansion, record free cash flow, and international growth, it also faced substantial challenges with revenue decline, eye care supply chain issues, and retail order volatility. The overall sentiment leans towards negative due to the significant impact of these challenges on short-term performance and guidance.View all PBH earnings summariesPBH Stock 12 Month Forecast
Average Price Target
$83.33
▲(34.75% Upside)
Technical Analysis
Cardinal Health
―
Henry Schein
―
McKesson
―
Owens & Minor
―
Guardian Pharmacy Services, Inc. Class A
―
Ownership Overview
1.29% Insiders
44.08% Mutual Funds
23.42% Other Institutional Investors
4.34% Public Companies and
Individual Investors